A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

BACKGROUND: Only a few prospective trials exist regarding the use of novel direct-acting antiviral agents (DAAs) in kidney transplant recipients (KTR) with chronic hepatitis C virus (HCV) infection. METHODS: This prospective single-center trial evaluated treatment with daclatasvir (DCV) and sofosbuv...

Descripción completa

Detalles Bibliográficos
Autores principales: Duerr, Michael, Schrezenmeier, Eva V., Lehner, Lukas J., Bergfeld, Léon, Glander, Petra, Marticorena Garcia, Stephan R., Althoff, Christian E., Sack, Ingolf, Brakemeier, Susanne, Eckardt, Kai-Uwe, Budde, Klemens, Halleck, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360788/
https://www.ncbi.nlm.nih.gov/pubmed/30717681
http://dx.doi.org/10.1186/s12882-019-1218-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360788/
https://www.ncbi.nlm.nih.gov/pubmed/30717681
http://dx.doi.org/10.1186/s12882-019-1218-0

Ejemplares similares